Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Type 2 Diabetes Drugs Linked to Severe Joint Pain

June 2, 2017 By Law Offices of Thomas J. Lamb, P.A.


Health Canada recently warned about the risk of severe, debilitating joint pain as a result of taking type 2 diabetes medications called dipeptidylpeptidase-4 (DPP-4) inhibitors.

This DPP-4 inhibitors class of drugs includes the following:

  • Onglyza
  • Kombiglyze XR
  • Nesina
  • Kazano
  • Oseni
  • Glyxambi
  • Janumet (XR)
  • Januvia
  • Jentadueto
  • Tradjenta
  • Qtern

The FDA also issued a Drug Safety Communication in August of 2015 concerning the association of DPP-4 inhibitors and severe joint pain.  They soon added the following warning to the labels for these drugs:

Severe and Disabling Arthralgia

There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.

The FDA’s warning and subsequent label change concerning DPP-4 inhibitors sparked an extensive review of the existing medical literature on the relationship between these drugs and severe joint pain.

Based on this literature review, as well as the FDA’s actions and their Adverse Event Reporting System, Health Canada is following suit and “working with manufacturers to update the product safety information for all DPP-4 inhibitors to communicate the risk of developing severe and disabling joint pain with the use of these drugs.”

It will be interesting to see if Health Canada decides to use a strengthened version of the FDA’s warning against disabling joint pain in their own warnings.

We will continue to monitor medical news and publications for new and increased warnings of the link between severe joint pain and the DPP-4 inhibitor class of drugs.

 

Written by: Heather Helmendach, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.


Drug Injury Watch
: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: diabetes drugs joint pain, diabetes drugs side effects, dipeptidylpeptidase-4 inhibitors, dpp-4 drugs, drugs side effects, Glyxambi, Janumet (XR), Januvia, Jentadueto, joint pain causes, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Qtern, Tradjenta, type 2 diabetes drugs

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.